SEC Filing Summary: Pieris Pharmaceuticals, Inc. (PIRS)
Business Context and Reporting Period
This Form 8-K was filed by Pieris Pharmaceuticals, Inc. on November 2, 2022. The filing serves as a current report to announce the Company's financial results for the quarter ended September 30, 2022, and to provide Regulation FD disclosure via an investor presentation.
Key Financial Metrics
The filing text itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the press release furnished as Exhibit 99.1 and the investor presentation furnished as Exhibit 99.2, which are not included in the provided source text.
Material Changes
No specific material changes or comparative financial data versus prior periods are disclosed within the body of this Form 8-K. The document acts solely as a notification that such results have been issued.
Guidance, Outlook, and Risks
The filing includes an Investor Presentation (Exhibit 99.2) which typically contains management commentary, outlook, and risk factors. However, the specific content of this presentation is not provided in the source text. The filing explicitly states that the information in Item 2.02 and Item 7.01 is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2022 revenue, net loss, and cash position figures.
- Examine Exhibit 99.2 (Investor Presentation) for updated clinical trial timelines, pipeline progress, and cash runway guidance.
- Verify the Company's liquidity status and any recent financing activities mentioned in the excluded exhibits.
- Confirm the trading status of Common Stock (PIRS) on The Nasdaq Capital Market.